GAROFALO HEALTH CARE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.1 EUR | -.--% |
|
+0.79% | +9.91% |
| May. 15 | Garofalo Health Care in the quarter increases profit and revenues | AN |
| May. 15 | Garofalo Health Care S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 471.5 | 433.4 | 491.1 | 327.4 | 411 | 451.5 | - | - |
| Enterprise Value (EV) 1 | 566.2 | 531.1 | 633.5 | 472.4 | 616.7 | 629.5 | 591.5 | 549.5 |
| P/E ratio | 36 x | 37.9 x | 26.2 x | 15.3 x | 25.8 x | 17.3 x | 16.5 x | 15.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.4 x | 2.06 x | 1.73 x | 1.01 x | 1.11 x | 0.98 x | 0.96 x | 0.94 x |
| EV / Revenue | 2.88 x | 2.52 x | 2.23 x | 1.46 x | 1.67 x | 1.36 x | 1.25 x | 1.14 x |
| EV / EBITDA | 14.8 x | 15.6 x | 11.9 x | 8.06 x | 9.19 x | 7.77 x | 7.13 x | 6.39 x |
| EV / FCF | -4.72 x | 123 x | 54.4 x | 16.3 x | - | 23.1 x | 15.6 x | 13.5 x |
| FCF Yield | -21.2% | 0.81% | 1.84% | 6.12% | - | 4.32% | 6.42% | 7.39% |
| Price to Book | 3.33 x | 2.34 x | 1.88 x | 1.17 x | - | - | - | - |
| Nbr of stocks (in thousands) | 81,859 | 81,773 | 89,298 | 88,966 | 88,578 | 88,529 | - | - |
| Reference price 2 | 5.760 | 5.300 | 5.500 | 3.680 | 4.640 | 5.100 | 5.100 | 5.100 |
| Announcement Date | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 196.5 | 210.8 | 283.7 | 322.6 | 368.7 | 463 | 472 | 482 |
| EBITDA 1 | 38.2 | 34 | 53.1 | 58.6 | 67.1 | 81 | 83 | 86 |
| EBIT 1 | 24 | 15.49 | 28.23 | 31.66 | 39.23 | 49 | 50 | 53 |
| Operating Margin | 12.21% | 7.35% | 9.95% | 9.82% | 10.64% | 10.58% | 10.59% | 11% |
| Earnings before Tax (EBT) 1 | 18.66 | 13.02 | 23.99 | 27.37 | 28.93 | 36 | 38 | 41 |
| Net income 1 | 13.14 | 11.78 | 18.83 | 21.43 | 20.8 | 26 | 28 | 30 |
| Net margin | 6.69% | 5.59% | 6.64% | 6.64% | 5.64% | 5.62% | 5.93% | 6.22% |
| EPS 2 | 0.1600 | 0.1400 | 0.2100 | 0.2400 | 0.1800 | 0.2940 | 0.3100 | 0.3380 |
| Free Cash Flow 1 | -120 | 4.315 | 11.65 | 28.9 | - | 27.2 | 38 | 40.6 |
| FCF margin | -61.07% | 2.05% | 4.11% | 8.96% | - | 5.87% | 8.05% | 8.42% |
| FCF Conversion (EBITDA) | - | 12.69% | 21.93% | 49.32% | - | 33.58% | 45.78% | 47.21% |
| FCF Conversion (Net income) | - | 36.63% | 61.83% | 134.89% | - | 104.62% | 135.71% | 135.33% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 89.9 | 133.5 | 64.38 | - | 80.41 | 85.88 | 166.3 | 70.28 | 86 | 92.28 | 94.38 | 186.7 | 76.47 | 126.1 |
| EBITDA | 8.747 | 24.74 | 7.72 | - | 14.33 | 16.84 | 31.17 | 11.15 | 16.28 | 18.76 | 19.49 | 38.25 | 12.72 | - |
| EBIT | 3.272 | - | 2.2 | - | 7.845 | 11.86 | 19.71 | 5.553 | 6.717 | 13.96 | 12.04 | 26.01 | 6.129 | - |
| Operating Margin | 3.64% | - | 3.42% | - | 9.76% | 13.82% | 11.85% | 7.9% | 7.81% | 15.13% | 12.76% | 13.93% | 8.02% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | 1.249 | 9.769 | - | 5.773 | - | - | - | - | - | - | - | - | - | 10.06 |
| Net margin | 1.39% | 7.32% | - | - | - | - | - | - | - | - | - | - | - | 7.97% |
| EPS | 0.0200 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 9/23/20 | 9/13/21 | 11/14/22 | 3/16/22 | 5/13/22 | 9/12/22 | 9/12/22 | 11/14/22 | 3/16/23 | 5/15/23 | 9/12/23 | 9/12/23 | 11/14/23 | 5/15/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 94.7 | 97.7 | 142 | 145 | 206 | 178 | 140 | 98 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.478 x | 2.873 x | 2.681 x | 2.475 x | 3.066 x | 2.198 x | 1.687 x | 1.14 x |
| Free Cash Flow 1 | -120 | 4.32 | 11.6 | 28.9 | - | 27.2 | 38 | 40.6 |
| ROE (net income / shareholders' equity) | 6.96% | 5.96% | 8.13% | 7.94% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 1.730 | 2.260 | 2.920 | 3.140 | - | - | - | - |
| Cash Flow per Share | - | - | 0.4100 | 0.4900 | - | - | - | - |
| Capex 1 | 8.81 | - | 24.7 | 15 | - | 18.5 | 18.9 | 20.8 |
| Capex / Sales | 4.48% | - | 8.7% | 4.64% | - | 4% | 4% | 4.32% |
| Announcement Date | 3/23/20 | 3/16/21 | 3/16/22 | 3/16/23 | 3/14/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.1
EUR
Average target price
6.5
EUR
Spread / Average Target
+27.45%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.91% | 490M | |
| -23.39% | 15.56B | |
| -2.70% | 11.65B | |
| +2.65% | 11.58B | |
| +2.37% | 10.06B | |
| -10.45% | 7.16B | |
| +8.05% | 6.85B | |
| -4.29% | 5.71B | |
| +13.33% | 4.3B | |
| -3.96% | 4.3B |
- Stock Market
- Equities
- GHC Stock
- Financials Garofalo Health Care S.p.A.
